Swedish-based gene therapy biotech Asgard Therapeutics has closed a €30 million ($32.6 million) Series A to advance its first-in-class in vivo cell reprogramming platform for immuno-oncology, the company announced Thursday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,